Alnylam Pharmaceuticals
ALNY
#650
Rank
S$41.38 B
Marketcap
$320.87
Share price
0.28%
Change (1 day)
25.51%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -$5.50

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -$5.63. In 2022 the company made an earnings per share (EPS) of -$12.72 a decrease over its 2021 EPS that were of -$9.86.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$5.50-56.8%
2022-$12.7229.03%
2021-$9.86-3.36%
2020-$10.20-8.48%
2019-$11.157.67%
2018-$10.3539.74%
2017-$7.4112.94%
2016-$6.5638.84%
2015-$4.73-32.88%
2014-$7.04259.44%
2013-$1.96-31.25%
2012-$2.8552.94%
2011-$1.8630.77%
2010-$1.42-8.77%
2009-$1.5678.13%
2008-$0.88-70.78%
2007-$3.0099.09%
2006-$1.51-43.88%
2005-$2.68-82.33%
2004-$15.19-59.23%
2003-$37.27

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$2.33-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
$51.17-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-$10.72 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.37-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-$2.31-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.12-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$4.36-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-$2.74-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel